ES2182973T3 - Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio. - Google Patents

Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.

Info

Publication number
ES2182973T3
ES2182973T3 ES96912798T ES96912798T ES2182973T3 ES 2182973 T3 ES2182973 T3 ES 2182973T3 ES 96912798 T ES96912798 T ES 96912798T ES 96912798 T ES96912798 T ES 96912798T ES 2182973 T3 ES2182973 T3 ES 2182973T3
Authority
ES
Spain
Prior art keywords
channel blockers
potassium channel
administration
intraocular pressure
mammal eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912798T
Other languages
English (en)
Inventor
Joseph S Adorante
Elizabeth Woldemussie
Guadalupe Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23710776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2182973(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2182973T3 publication Critical patent/ES2182973T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCUBREN COMPOSICIONES FARMACEUTICAS Y UN METODO PARA TRATAR EL GLAUCOMA Y/O LA HIPERTENSION OCULAR EN OJO DE MAMIFERO ADMINISTRANDO AL OJO DE MAMIFERO LA COMPOSICION FARMACEUTICA DE LA INVENCION QUE CONTIENE, COMO INGREDIENTE ACTIVO, UNO O MAS COMPUESTOS CON ACTIVIDAD BLOQUEADORA DE CANALES DE POTASIO. SON EJEMPLOS DE BLOQUEADORES DE CANALES DE POTASIO UTILIZADOS EN LA COMPOSICION FARMACEUTICA Y METODO DE TRATAMIENTO QUININA, ALCALOIDES DE INDOL TREMOGENICOS TALES COMO PENITREM A Y PASPALICINA, Y TOXINAS DE INSECTOS TALES COMO CARIBDOTOXINAS E IBERIOTOXINA.
ES96912798T 1995-04-28 1996-04-16 Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio. Expired - Lifetime ES2182973T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/431,170 US5573758A (en) 1995-04-28 1995-04-28 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Publications (1)

Publication Number Publication Date
ES2182973T3 true ES2182973T3 (es) 2003-03-16

Family

ID=23710776

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02009867T Expired - Lifetime ES2204879T5 (es) 1995-04-28 1996-04-16 Neuroprotector para el ojo de mamiferos mediante administracion de bloqueadores del canal de potasio.
ES96912798T Expired - Lifetime ES2182973T3 (es) 1995-04-28 1996-04-16 Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02009867T Expired - Lifetime ES2204879T5 (es) 1995-04-28 1996-04-16 Neuroprotector para el ojo de mamiferos mediante administracion de bloqueadores del canal de potasio.

Country Status (8)

Country Link
US (1) US5573758A (es)
EP (2) EP0825863B1 (es)
JP (2) JPH11504330A (es)
AT (2) ATE225658T1 (es)
AU (1) AU703241B2 (es)
DE (2) DE69630325T3 (es)
ES (2) ES2204879T5 (es)
WO (1) WO1996033719A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
WO2001052876A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2434485A1 (en) * 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE60225420T2 (de) * 2001-01-30 2009-03-26 Merck & Co., Inc. Verfahren zur identifizierung von maxi-k-kanal-blockern
US20040115739A1 (en) * 2002-01-25 2004-06-17 Garcia Maria L Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040029771A1 (en) * 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
AU2003216547A1 (en) * 2002-03-15 2003-09-29 Merck And Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
CA2488802A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2003247533B2 (en) * 2002-06-17 2008-09-18 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
JP2005538061A (ja) * 2002-06-17 2005-12-15 メルク　エンド　カムパニー　インコーポレーテッド 新規ｍａｘｉ−ｋチャネルブロッカー、その使用方法および製造方法
CA2505127A1 (en) * 2002-11-08 2004-05-27 James B. Doherty Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004087051A2 (en) 2003-03-27 2004-10-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN1816530A (zh) * 2003-07-01 2006-08-09 麦克公司 用于治疗高眼压症的眼用组合物
CN1845914A (zh) * 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
KR20060090801A (ko) * 2003-09-04 2006-08-16 머크 앤드 캄파니 인코포레이티드 고안압증 치료용 안용 조성물
WO2005025568A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20050250779A1 (en) * 2004-05-04 2005-11-10 Song Zhu Pteridinone derivatives for treating ocular hypertension
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
US20070293558A1 (en) * 2004-10-13 2007-12-20 Ying-Duo Gao Ophthalmic Compositions for Treating Ocular Hypertension
CN101198325A (zh) * 2004-10-13 2008-06-11 默克公司 用于治疗高眼压的眼用组合物
EP2004193A2 (en) * 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2009541219A (ja) * 2006-06-12 2009-11-26 メルク エンド カムパニー インコーポレーテッド 高眼圧治療のための眼科組成物
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
EP2436387B1 (en) * 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010757A1 (en) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
EP0430621A3 (en) * 1989-11-29 1992-03-04 Beecham Group P.L.C. Process for the preparation of chiral 3,4-epoxy benzopyrans
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
AU7099194A (en) * 1993-06-08 1995-01-03 Vide Pharmaceuticals Methods and compositions for lowering intraocular pressure
US5494895A (en) * 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans

Also Published As

Publication number Publication date
EP1243270B2 (en) 2009-03-25
EP0825863B1 (en) 2002-10-09
AU5548896A (en) 1996-11-18
ATE225658T1 (de) 2002-10-15
EP1243270A1 (en) 2002-09-25
DE69624234D1 (de) 2002-11-14
DE69630325T3 (de) 2009-11-19
WO1996033719A1 (en) 1996-10-31
JPH11504330A (ja) 1999-04-20
ATE251458T1 (de) 2003-10-15
EP0825863A1 (en) 1998-03-04
ES2204879T3 (es) 2004-05-01
DE69630325T2 (de) 2004-07-29
EP1243270B1 (en) 2003-10-08
ES2204879T5 (es) 2009-06-19
DE69630325D1 (de) 2003-11-13
JP2007217437A (ja) 2007-08-30
US5573758A (en) 1996-11-12
AU703241B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
ES2969758T3 (es) Composiciones farmacéuticas para usar en la terapia de la blefaritis
US20060177430A1 (en) Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
US20150031629A1 (en) Ophthalmic formulation derived from silk protein
CY1114048T1 (el) Συνδυασμος βριμονιδινης και τιμολολης για τοπικη οφθαλμικη χρηση
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
BR112023006371A2 (pt) Composição oftalmológica tópica
RU2624534C2 (ru) Растворы биматопроста и тимолола, не содержащие консервантов
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
US20230172969A1 (en) Ophthalmic Composition
MX2024003580A (es) Metodos de tratamiento de enfermedades inflamatorias oculares.
KR102582048B1 (ko) 점안제
ES2177543T3 (es) Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
US20170224771A1 (en) Histatins as therapeutic agents for ocular surface disease
Niederkorn et al. The immunobiology of Acanthamoeba keratitis
TW201340963A (zh) 包含香葉基香葉基丙酮之眼科用組成物
HK1252301A2 (zh) 一种含有重组人溶菌酶的新型人工泪液
KR20220068131A (ko) 세티리진 및 토코페솔란을 포함하는 안과용 조성물
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
IT1295423B1 (it) Uso della flunarizina nella terapia topica del glaucoma
MXPA04000980A (es) Tratamiento de hipertension ocular y glaucoma.
JP6687781B1 (ja) 刺激感が抑制された眼科組成物